louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04504890: Ocular-vestibular Biomarker Identification for ADHD
Official title: Ocular-vestibular Biomarker Identification for ADHD
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: ADHD - Combined Type
ADHD
ADHD Predominantly Inattentive Type
ADHD, Predominantly Hyperactive - Impulsive
Keywords: ADHD
EYE-SYNC
eye tracking
oculomotor
vestibular
Lead sponsor: Sync-Think, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Sutter Health
First posted: 2020-08-07
Enrollment: 240
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children and adults seeking diagnosis and/or treatment for attention-related disorder.

Brief summary: This study intends to establish a relationship between oculovestibular eye tracking measures, measures of ADHD, and medication prescribed for ADHD.

Detailed description: This study will use a predictive visual tracking paradigm (SyncThink EYE-SYNC eye tracking paradigm) to dynamically capture the participants' attentional state. It will examine the validity of the eye tracking paradigm in identifying the disruption in attentional networks caused by ADHD by examining the association between eye tracking performances and well-established standardized measures of ADHD.

Eligibility criteria: Inclusion Criteria:

* Men and women ages 6-70 seeking evaluation and treatment for ADHD.

Exclusion Criteria:

* Clinical diagnosis of a neurological condition including the following: stroke, multiple sclerosis, epilepsy, brain tumor/cancer, dyslexia, nystagmus and/or other major neurological condition.

  * Clinical diagnosis of any of the following eye-sight abnormalities: uncorrected amblyopia, uncorrected myopia, uncorrected presbyopia, uncorrected farsightedness or uncorrected Astigmatism.
  * Psychiatric history with any of the following:
* LIFETIME: Clinical diagnosis of a psychotic disorder; bipolar disorder
* LAST YEAR: Clinical diagnosis of major depressive disorder; PTSD; clinical diagnosis of substance abuse disorder; major anxiety disorder

  * Use of a psychotropic medication
  * Impairment of cranial nerves II-VI
  * Participants who receive a 'Poor' or 'Fair' eye tracking quality result on either their baseline or follow-up evaluations will be excluded from analysis. Subjects may not repeat participation

Primary outcomes:
measure: Eye Tracking and ADHD measure correlation
timeFrame: through study completion, an average of 1 year
measure: Eye Tracking ADHD Diagnostic ROC
timeFrame: through study completion, an average of 1 year
measure: MANCOVA Eye Tracking in ADHD Treatment Population
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: San Carlos
country: United States
facility: Palo Alto Medical Foundation - San Carlos Center
state: California
Study officials:
References:
Clinical trial NCT00070590: Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma
Official title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Bosentan in Patients With Interstitial Lung Disease Associated With Systemic Sclerosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Pulmonary Fibrosis
Scleroderma, Systemic
Keywords: Scleroderma
Fibrosing alveolitis
Build
bosentan
Lead sponsor: Actelion
Sponsor class: INDUSTRY
First posted: 2003-10-08
Enrollment: 132
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Clinical and experimental studies suggest that bosentan could delay the progression of interstitial lung disease (ILD) associated with systemic sclerosis (SSc), a condition for which no established efficacious treatment is available. The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO Class III and IV, to a new category of patients suffering from ILD associated with SSc.


Eligibility criteria: Main inclusion criteria:

* Systemic Sclerosis diffuse or limited
* Significant Interstitial Lung Disease on HRCTscan
* DLco \< 80% predicted
* Dyspnea on exertion
* Walk not limited by musculoskeletal reasons

Main exclusion criteria:

* Interstitial Lung Disease due to other conditions than SSc
* End stage restrictive or obstructive lung disease
* Severe cardiac or renal diseases
* Significant pulmonary arterial hypertension
* Smoker (\> 5cig./day)
* Treatment with immunosuppressive, antifibrotic drugs, high dose corticosteroids (within 4 weeks of randomization)

Primary outcomes:
measure: Change from baseline to End-of-Study in 6-minute walk distance.
Secondary outcomes:
measure: Time to death (all causes) or to worsening of PFTs up to End-of-Study.
measure: Worsening of PFTs (on 2 consecutive tests at least 4 weeks apart) is defined as: decrease from baseline ≥ 10% in FVC OR decrease from baseline ≥ 15% in DLco AND ≥ 6% in FVC
Other outcomes:
Locations:
Study officials:
References:
citation: Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2021 Mar 26;3(3):CD004434. doi: 10.1002/14651858.CD004434.pub6.
citation: Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, Matucci Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S, Black CM. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum. 2010 Jul;62(7):2101-8. doi: 10.1002/art.27466.
Clinical trial NCT06812390: Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites
Official title: Albumin Assisted Diuresis in Patients with Cirrhosis Decompensated by Ascites and Peripheral Edema, a Proof-of-concept Double Blind Randomized Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Cirrhosis
Ascites Hepatic
Keywords: albumin
cirrhosis
ascites
diuresis
Lead sponsor: VA Connecticut Healthcare System
Sponsor class: FED
Collaborators: name: Grifols Shared Services North America Inc
First posted: 2025-02-06
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Proof of concept, randomized, cross over, double-blind placebo-controlled study
Primary purpose: OTHER

Brief summary: A small, pilot proof-of-concept placebo-controlled trial to explore the effects of albumin on diuresis in patients with cirrhosis, ascites and lower extremity edema. We will additionally investigate albumin's effect on preventing neurohumoral activation, and acute kidney injury after diuresis.


Eligibility criteria: Inclusion Criteria:

* Outpatient patients with decompensated cirrhosis with past or current ascites and persistent lower extremity edema despite oral diuretic titration
* Serum albumin of \< 3.5 g/dL
* Age \>=18 years old

Exclusion Criteria:

* Patients with GFR \< 30mL/min/1.73 m2
* Changes in oral diuretic regimen in the past 7 days (\*\*patients can enter the study after 7 days of the change)
* Large Volume paracentesis (LVP) in the past 7 days (\*\*patients can enter the study after 7 days)
* Albumin infusion within the previous 14 days (\*\* patients can enter the study after 14 days)
* Spontaneous Bacterial Peritonitis in the past month
* Active variceal bleeding
* Current Hepatic encephalopathy (\>= Grade 2 based on West Haven criteria)
* Co-administration of other diuretics such as Hydrochlorothiazide (amiloride or eplerenone in place of spironolactone, and Bumex/Torsemide in place of furosemide are acceptable)
* Hypotension (Mean Arterial Pressure \<65 mmHg, Systolic Blood pressure \<90 mmHg)
* Severe hyponatremia (Sodium \<125 mEq/L)
* previous diagnosis of overt heart failure (systolic EF \< 50%)
* Baseline oxygen requirement
* Hypersensitivity to albumin preparations

Primary outcomes:
measure: Change in fractional excretion of sodium (FENa)
timeFrame: 6 hours (baseline vs hour 6 after albumin vs placebo administration)
Secondary outcomes:
measure: Changes in neuro hormonal markers
timeFrame: 6 hours and 24 hours
Other outcomes:
Locations:
city: West Haven
country: United States
facility: West Haven VA Medical Center
state: Connecticut
Study officials:
References:
Clinical trial NCT00747890: Surgical Treatment of Mild Obstructive Sleep Apnea
Official title: The Effects of Surgical Treatment on Mild Obstructive Sleep Apnea and Its Co-morbidities
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sleep Apnea
Lead sponsor: Kuopio University Hospital
Sponsor class: OTHER
First posted: 2008-09-05
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Obstructive sleep apnea (OSA) is one of the most common sleep disorder. There are numerous conditions that are related to OSA, such as diabetes, cardiovascular diseases, and metabolic syndrome. If the patient with OSA have large tonsils, soft and largened uvula or flacid soft palate, one might benefit from operative treatment of OSA. The aim of our study is to find out whether an operative treatment is effective in mild OSA patients with carefully assessed anatomical predispositions. Our ultimate goal is to evaluate the effects of operative treatment in mild OSA itself and in the diseases related to OSA. We measure the cardiovasculary functions, symptoms, postoperative recovery, antropometry, laboratory tests, the quality of life, the quality of sleep and the inflammatory system in sleep apnea before and after the surgery.


Eligibility criteria: Inclusion Criteria:

* Age 18-65
* BMI \<35
* AHI 5-30 events/h
* Largened tonsils Grade ≥1

Exclusion Criteria:

* Age \<18 or \> 65
* BMI \>35
* AHI \<5 or \>30
* Tonsil size \< 1
* Severe nasal polyposis
* Pregnancy
* Chronic kidney, liver or thyroid disease
* Active treatment of OSA of any kind

Primary outcomes:
measure: Apnea Hypopnea Index
timeFrame: One year(before and after surgery)
Secondary outcomes:
measure: Quality of life
timeFrame: One Year
Other outcomes:
Locations:
city: Kuopio
country: Finland
facility: Kuopio University Hospital
Study officials:
References:
Clinical trial NCT02186990: Comparison of Etomidate, Propofol and Etomidate-propofol Combination in Terms of Effects on Haemodynamic Response to Intubation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Induction of Anaesthesia
Lead sponsor: T.C. ORDU ÜNİVERSİTESİ
Sponsor class: OTHER
First posted: 2014-07-10
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the effect of propofol, etomidate and propofol-etomidate combination on hemodynamic responses during laryngoscopy and tracheal intubation and assess the adverse effect related to this drugs.


Eligibility criteria: Inclusion Criteria:

* between 18 - 65 age
* ASA I - II status
* elective surgery

Exclusion Criteria:

* emergency surgery
* pregnancy
* alcohol and drug abuse
* HT and cardiovascular disease
* BMI \> 25 kg/m2
* hypersensitivity against study drug
* sedative drug use in last month
* difficult intubation

Primary outcomes:
measure: haemodynamic values
timeFrame: in ten minutes after intubation
Secondary outcomes:
measure: adverse effect of study drugs
timeFrame: within in 30 minutes drug administration
Other outcomes:
Locations:
city: Altınordu
country: Turkey
facility: Anesthesiology and Reanimation Dept. Ordu University Training and Research Hospital
state: Ordu
Study officials:
References:
Clinical trial NCT02033590: Clinical and Economic Outcomes With the Use of SERI® Surgical Scaffold in Direct-to-implant Breast Reconstruction
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Breast Reconstruction
Lead sponsor: Sofregen Medical, Inc.
Sponsor class: INDUSTRY
First posted: 2014-01-13
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this study is to prospectively observe clinical and economic outcomes with the use of SERI® in direct-to-implant breast reconstruction.


Eligibility criteria: Inclusion Criteria:

* Be willing to undergo immediate breast reconstruction following a skin-sparing or nipple sparing mastectomy with healthy, sufficiently thick, well-vascularized skin flaps, and the implantation of SERI® Surgical Scaffold and breast implant
* Be female, between 18 and 65 years of age at the time of enrollment

Exclusion Criteria:

* Have undergone prior radiation treatment on the study breast(s) and/or is preoperatively evaluated to require radiation treatment to the study breast(s) during the course of the study
* Have undergone a skin reducing mastectomy
* Have a BMI that is \<17 or ≥ 30
* Predicted implant weight more than 500 grams
* Have a known allergy to silk
* Have an abscess or active infection at any location within one month prior to surgery
* Be pregnant, lactating, or if of childbearing potential, be unwilling to use contraceptive methods and avoid pregnancy throughout the study

Primary outcomes:
measure: Incidence rate of implant loss (SERI® and breast implant)
timeFrame: 52 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05644990: T2MR PCR Detection of ESKAPE Pathogens in Patients With Pyogenic Spondylodiscitis and Infective Endocarditis
Official title: Direct Detection of ESKAPE Pathogens From Whole Blood Using T2MR Bacteria Panel in Patients With Pyogenic Spondylodiscitis and Infective Endocarditis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Osteomyelitis; Vertebra
Endocarditis, Bacterial
Keywords: Spondylodiscitis
Endocarditis
PCR
T2Bacteria Panel
MRI
Lead sponsor: Charles University, Czech Republic
Sponsor class: OTHER
Collaborators: name: Bulovka Hospital
name: University Hospital, Motol
First posted: 2022-12-09
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients diagnosed with pyogenic spine infections and/or infective endocarditis, treated at the standard care wards and ICU of the Department of infectious diseases and Department of orthopaedics of the University Hospital Bulovka.

Brief summary: Our prospective observational study focuses on the rapid detection of etiologic agents of pyogenic spondylodiscitis and infective endocarditis using the T2 Bacteria Panel (T2Biosystems). This diagnostic method combines polymerase chain reaction (PCR) and T2 magnetic resonance for detection of bacterial DNA from whole blood samples. It detects six pathogens known by the acronym ESKAPE (E. coli, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and E. faecium). In recent years, similar studies using the Bacteria Panel and Candida Panel have been performed in patients with bloodstream infections, leaving us with optimistic results.The aim of this study is to verify whether T2B can identify the etiologic agents of localized infections, specifically spondylodiscitis and endocarditis, with better sensitivity and specificity and shorter time to result compared to conventional diagnostics from blood culture. Rapid detection of pathogen may reduce time to targeted pathogen-specific antibiotic therapy and subsequently improve outcomes, shorten the treatment and contribute to slowing the development of antibiotic resistance.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of spondylodiscitis or/and facet joint infection or/and sacroileitis
* Diagnosis of infective endocarditis
* Antibiotic treatment not received or not longer than 24 hours
* Ability to give informed consent

Exclusion Criteria:

* Spine infection or/and endocarditis not confirmed
* Antibiotic treatment longer than 24 hours
* Inability to give informed consent

Primary outcomes:
measure: Sensitivity and Specificity of the T2 Bacteria Panel
timeFrame: 3 years
measure: Expected treatment outcomes in patients diagnosed by T2 Bacteria Panel
timeFrame: 4 years
Secondary outcomes:
measure: Diagnostic utility of T2 Bacteria Panel in other localized infections
timeFrame: 4 years
Other outcomes:
Locations:
city: Prague
country: Czechia
facility: University Hospital Bulovka
Study officials:
References:
Clinical trial NCT00786890: A Survey to Evaluate the Cardiovascular Risk Status of Subjects With Pre-Diabetes in Hong Kong
Official title: A Survey to Evaluate the Cardiovascular Risk Status of Subjects With Pre-Diabetes in Hong Kong: The Joint Asia Diabetes Evaluation (JADE) Program Sub-study 2 (JADE-HK2)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Prediabetes
Cardiovascular Risk Factors
Keywords: Prediabetes (IFG, IGT)
Hong Kong Chinese
Cardiovascular risk factors
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2008-11-06
Enrollment: 3000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hong Kong Chinese with pre-diabetes

Brief summary: Hypothesis: A high cardiovascular risk is present in subjects with pre-diabetes in Hong Kong Chinese.

The investigators plan to assess Chinese subjects in Hong Kong who have pre-diabetes (impaired fasting glucose, IFG; or impaired glucose tolerance, IGT) based on oral glucose tolerance test (OGTT) on their cardiovascular risk status such as obesity, hypertension and lipid profile.


Eligibility criteria: Inclusion Criteria:

* Hong Kong Chinese with confirmed IFG or IGT by OGTT

Exclusion Criteria:

* Confirmed diabetic patients

Primary outcomes:
measure: Cardiovascular risk factors: anthroprometric parameters, blood pressure and lipid profiles
timeFrame: instant
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: Hong Kong Institute of Diabetes and Obesity
Study officials:
References:
Clinical trial NCT05399290: Subantimicrobial Doxycycline in Acne
Official title: A Randomized Controlled Trial Investigating the Pediatric Patient Experience of Subantimicrobial Dose Doxycycline for Acne Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Acne Vulgaris
Pediatrics
Keywords: Acne Vulgaris
Doxycycline
Sub-Antimicrobial
Pediatrics
Lead sponsor: Michigan State University
Sponsor class: OTHER
First posted: 2022-06-01
Enrollment: 22
Sex: ALL
Minimum age (years): 13
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Antibiotic resistance is a public health problem that worsens the more physicians prescribe standard dose antibiotics for acne. Regardless of race, acne vulgaris is one of the most common dermatologic conditions among pediatric populations. As such, clinicians can make a large impact by practicing good antibiotic stewardship while still addressing the impact of acne on adolescents' self-esteem. Subantimicrobial doxycycline maintains its anti-inflammatory effects while eliminating antimicrobial properties and associated risks of drug resistance. Few studies, focused primarily on adults, have shown that subantimicrobial doxycycline is efficacious in treating acne from a physician standpoint. The investigators aim to investigate the patient experience of acne treatment with subantimicrobial dose doxycycline in the pediatric population.


Eligibility criteria: Inclusion Criteria:

* Documented moderate to severe facial acne

Exclusion Criteria:

* Other skin conditions on the face
* Previous antibiotic treatment for acne
* Use of antibiotics for any reason within the past month
* Use of new prescription regiment for acne within the last 3 months
* Positive pregnancy test in the clinic
* Cognitive impairments

Primary outcomes:
measure: Patient Perceptions of Their Acne Treatment
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
measure: Changes in Medication, Open Comments in the Qualtrics Survey Regarding Acne Treatment
timeFrame: 12 weeks
measure: Side Effects
timeFrame: 12 weeks
Locations:
city: Lansing
country: United States
facility: Messenger Dermatology Clinic
state: Michigan
Study officials:
affiliation: Michigan State University
name: Michelle Gallagher, DO
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05258890: TEAMS-BP (The Enhancement of Social Networks to Augment Management of Stroke-Blood Pressure)
Official title: TEAMS-BP (The Enhancement of Social Networks to Augment Management of Stroke-Blood Pressure): A Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Stroke, Acute Ischemic
Hypertension
Keywords: Social Networks
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
Collaborators: name: National Institute on Aging (NIA)
First posted: 2022-02-28
Enrollment: 64
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to compare the efficacy of a social network intervention versus individual hypertension counseling to improve blood pressure control after stroke. The investigators hope to understand whether the involvement of family, friends and other members of individual's social network can help achieve better blood pressure after experiencing a stroke. Participants will be stratified to two groups according to network size (\<5 vs 5 or more) and randomized to receive individual hypertension counseling (control) or the social network intervention. The primary outcome of the study will be the absolute reduction in systolic blood pressure at 3 months follow-up. The secondary outcomes will be attainment of a post-stroke hypertension treatment goal and patient-reported physical function.


Eligibility criteria: Inclusion Criteria:

1. First acute ischemic stroke defined clinically with support from imaging if necessary
2. 21 years of age or older
3. Within 14 days after stroke
4. History of hypertension or has been newly prescribed blood pressure medications during index admission

Exclusion Criteria:

1. Prior ischemic or hemorrhagic stroke
2. NIHSS \> 21
3. Significant aphasia (Score\>1 on the language section of the NIHSS)
4. Medical conditions for which death is likely within 6 months
5. Does not have capacity to consent for the project or participate in survey interview
6. Diagnosis of dementia
7. Patient has no phone or incapable of using text messages
8. Patient has opted out of participating in research noted within MGB Epic EHR system

Primary outcomes:
measure: Change in Systolic Blood Pressure for Patient-Subjects
timeFrame: baseline and 3 months
Secondary outcomes:
measure: Achievement of Post-stroke Hypertension Treatment Goal for Patient-Subjects
timeFrame: 3 months
measure: Patient Reported Physical Function for Patient-Subjets
timeFrame: 3 months
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
Study officials:
affiliation: Brigham and Women's Hospital
name: Amar Dhand, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: